ST 1535

• Description :

  ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Adenosine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/st-1535.html

• Purity :

  99.80

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CN1C(N2N=CC=N2)=NC3=C1N=C(CCCC)N=C3N

• Molecular Formula :

  C12H16N8

• Molecular Weight :

  272.31

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Stasi MA, et al. ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol. 2006 Oct;9 (5) :575-84.|[2]Tronci E, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566 (1-3) :94-102.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Adenosine A2A receptor (A2AR)

• CAS Number :

  [496955-42-1]